Status:
COMPLETED
Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B
Lead Sponsor:
Yaşar Bayındır, MD
Collaborating Sponsors:
Nobel Pharmaceuticals
Conditions:
Chronic Hepatitis B
Hepatic Steatosis
Eligibility:
All Genders
18-65 years
Brief Summary
The aim of the study was to evaluate the consistency between liver biopsy and Liver Stiffness Measurement (LSM) for fibrosis and controlled attenuation parameter (CAP) for steatosis in FibroScan® in p...
Detailed Description
Patients aged 18 years and older with HBsAg positivity for more than six months and HBV-DNA level \>2,000 IU/ml were included in the study. The exclusion criteria were established as presence of cirrh...
Eligibility Criteria
Inclusion
- Patients aged 18 years and older with HBsAg positivity for more than six months
- Patients have HBV-DNA level \>2,000 IU/ml for more than six months
Exclusion
- Presence of cirrhosis
- Alcohol consumption \>140 g/week in women and 210 g/week in men
- Hepatitis C coinfection
- Hepatitis D and/or HIV coinfections
Key Trial Info
Start Date :
January 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06573190
Start Date
January 2 2023
End Date
May 15 2024
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guven Hospital
Ankara, Turkey (Türkiye), TR-06540